Phase I Clinical Study Combining L19-IL2 With Stereotactic Ablative Body Radiotherapy in Patients With Oligometastatic Solid Tumor
Phase of Trial: Phase I
Latest Information Update: 02 Jun 2017
At a glance
- Drugs L19-IL2 fusion protein (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms L19-IL2
- 30 May 2017 Status changed from discontinued to completed.
- 22 May 2017 Planned End Date changed from 1 Mar 2017 to 1 Jun 2017.
- 22 May 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Jun 2017.